Abiopharma

🔍 Behrenbruch Christian (Director)

Company: Telix Pharmaceuticals Ltd (TLX)

Report Date: 2026-04-28

Detailed Transactions and Holdings:

• Acquired 34,500 shares of Ordinary Shares at $14.48 per share (Direct)
  Date: 2026-04-28 | Code: P | equity_swap_involved: 0 | shares_owned_after: 20,709,500.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Acquired 33,435 shares of Ordinary Shares at $14.87 per share (Direct)
  Date: 2026-04-29 | Code: P | equity_swap_involved: 0 | shares_owned_after: 20,742,935.00 | transaction_form_type: 4 | Footnotes: F2, F3

Footnotes:

• F1: The price reported in Column 4 is an average price. The shares were purchased in multiple transactions at prices ranging from $14.42 - $14.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (SEC), upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
• F2: The purchase prices are reported in Australian Dollars.
• F3: Dr. Behrenbruch is the sole director and shareholder of Elk River Holdings Pty Ltd.
• F4: The price reported in Column 4 is an average price. The shares were purchased in multiple transactions at prices ranging from $14.54 - $14.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.